围产期抗凝管理
妊娠期血栓风险升高,抗凝药是孕期常用药物之一。本文围绕产前抗凝患者的分娩计划,讨论预防性与治疗性剂量、分娩方式、计划分娩与自然分娩、椎管内麻醉指征及患者偏好等要点,强调血栓专家、产科与麻醉科产前协作制定个体化方案,并回顾产后抗凝选择与依从性。讨论仅限静脉血栓栓塞症指征的抗凝。
要点
- 产前抗凝患者应提前规划分娩,平衡继续抗凝的获益与产后出血及椎管内麻醉受限的风险。
- 分娩计划需考虑预防性与治疗性剂量、分娩方式、计划与自然分娩、椎管内麻醉指征及患者偏好。
- 血栓专家、产科与麻醉科应产前协作制定个体化分娩方案,并关注产后抗凝依从性。
核心结论
- 产前抗凝患者的最佳管理需要血栓专家、产科医生和麻醉科医生产前协作,制定兼顾血栓风险、出血并发症可能性和患者偏好的个体化分娩计划。
研究设计与样本
- 本文为综述,讨论范围限于静脉血栓栓塞症指征的抗凝管理。
主要发现
- 妊娠期血栓风险升高,抗凝药是孕期最常处方的药物之一。
- 围产期抗凝管理必须平衡继续治疗的获益与产后出血风险及提供椎管内麻醉的潜在限制。
- 分娩计划的关键考虑包括预防性与治疗性剂量、分娩方式(阴道分娩与剖宫产)、计划分娩与自然分娩、椎管内麻醉的具体指征(如双胎妊娠和困难气道)、患者对椎管内麻醉的重视程度,以及适用时静脉血栓栓塞症诊断至今的时间。
- 对于因中断治疗性抗凝而风险高的患者,需评估是否在分娩前将低分子量肝素转换为皮下普通肝素用于预防或普通肝素持续输注。
- 产后抗凝选择应强调在这一高风险时期坚持用药的重要性。
临床怎么用
- 产前抗凝患者应提前规划分娩,以安全且以患者为中心的方式平衡血栓与出血风险。
- 分娩计划需个体化考虑预防性与治疗性剂量、分娩方式、计划与自然分娩、椎管内麻醉指征、患者对椎管内麻醉的偏好及静脉血栓栓塞症诊断至今的时间。
- 血栓专家、产科医生和麻醉科医生应产前协作制定个体化分娩计划。
- 对因中断治疗性抗凝而高风险的患者,可评估分娩前将低分子量肝素转换为皮下普通肝素预防或普通肝素持续输注。
- 产后应关注抗凝依从性,强调在这一高风险时期坚持用药。
局限性
- 本文讨论仅限于静脉血栓栓塞症指征的抗凝管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Due to the elevated thrombosis risk during pregnancy, anticoagulants are among the most common medications prescribed during gestation. For patients on anticoagulation antepartum, planning for delivery in advance is central to a safe and patient-centered delivery. Peripartum anticoagulation management must balance the benefits of continued therapy against the risks of postpartum hemorrhage and potential limitations in offering neuraxial anesthesia. Key considerations for delivery planning for patients on anticoagulation include the following: (1) prophylactic versus therapeutic dosing; (2) mode of delivery (vaginal vs cesarean); (3) scheduled vs spontaneous delivery; (4) specific indications for neuraxial anesthesia (eg, twin gestation and difficult airway); (5) the patient's valuation of neuraxial anesthesia; and (6) time since diagnosis of venous thromboembolism where applicable. Optimal patient management requires prenatal collaboration among thrombosis experts, obstetricians, and anesthesiologists to develop a personalized plan for delivery that balances risk of thrombosis, the potential for hemorrhagic complications, and patient preferences. This includes evaluating whether a patient on low-molecular-weight heparin should switch prior to delivery to subcutaneous unfractionated heparin for prophylaxis or unfractionated heparin continuous infusion, for those at high risk from a break in therapeutic anticoagulation. We also review postpartum anticoagulation options, emphasizing the importance of adherence during this high-risk period. Our discussion is limited to anticoagulation indicated for venous thromboembolism.
引用
- Langer AL, Togioka B, Smith NA, et al. Managing anticoagulation peripartum. J Thromb Haemost. 2025. PMID: 41015159. doi:10.1016/j.jtha.2025.09.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。